Stryker (NYSE:SYK) Director Ronda Stryker Sells 300,000 Shares of Stock

Key Points

• Director Ronda Stryker sold 300,000 shares at an average price of $335.90, generating approximately $100.77 million. Her direct ownership declined 11.53% to 2,301,375 shares.
• Stryker shares fell 3.5% to $327.97, while the company’s latest quarterly results exceeded expectations with adjusted EPS of $3.69 and revenue of $6.59 billion, up 9.4% year over year.
• The company declared a quarterly dividend of $0.88 per share, or $3.52 annualized, representing a 1.1% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $386.28.

Stryker Corporation (NYSE:SYK - Get Free Report) Director Ronda Stryker sold 300,000 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Stryker Trading Down 3.5%

SYK stock traded down $12.01 during mid-day trading on Thursday, reaching $327.97. 2,232,012 shares of the stock traded hands, compared to its average volume of 2,368,609. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The stock has a market capitalization of $125.80 billion, a PE ratio of 33.99, a PEG ratio of 2.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The business has a 50-day moving average price of $326.19 and a two-hundred day moving average price of $332.95.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm's revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent research reports. Piper Sandler reduced their price target on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Barclays lowered their price target on Stryker from $469.00 to $394.00 and set an "overweight" rating for the company in a report on Monday, May 4th. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a report on Friday, May 1st. Finally, Argus set a $370.00 target price on Stryker in a report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $386.28.

Institutional Investors Weigh In On Stryker

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Gables Capital Management Inc. acquired a new position in shares of Stryker in the second quarter worth about $25,000. Kilter Group LLC acquired a new position in Stryker in the 2nd quarter worth about $25,000. Godfrey Financial Associates Inc. purchased a new position in Stryker during the fourth quarter worth approximately $26,000. Sankala Group LLC acquired a new stake in Stryker in the fourth quarter valued at approximately $26,000. Finally, Compass Financial Management LLC purchased a new stake in shares of Stryker in the second quarter valued at approximately $27,000. Institutional investors and hedge funds own 77.09% of the company's stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source